By my estimation, Eficonazole is approved and yet we don't have anyone selling it. Jublia (Eficonazole's brand name) 'exclusivity' expires April 27, 2023, though the patents themselves go for years. Acrux's settlement with Jublia over when they would be able to go to market was announced as confidential mid-2021.
The next two pending approval seem to be either the two strengths of Dapsone; or Dapsone on the one hand and Acyclovir on the other. In any case, expected to be approved in the first half of 2023.
Any thoughts as to what's next?
ACR Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
